IMNEWRUN

IMNEWRUN is a biotechnology startup founded in 2019 with a mission to create transformative solutions for patients with brain diseases. The company focuses on developing next-generation blood-brain barrier-penetrating antibodies to address the unmet needs in this area. IMNEWRUN sets itself apart through its learning platform, which fosters innovation by facilitating interaction between students, faculty, and industry experts to create exponential learning opportunities. This synergy accelerates scientific discoveries and the development of next-generation treatment modalities. Based in South Korea, IMNEWRUN is driven by a team of passionate scientists and professionals who are dedicated to serving humanity through biotechnology. The company's commitment to understanding fundamental science and inspiring lives underscores its potential to make a significant impact. While IMNEWRUN's last investment details are currently unavailable, the innovation-driven ethos and the company's focus on critical medical needs position it as a promising venture for potential investors to consider.